Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from ImmuPharma ( (GB:IMM) ) is now available.
ImmuPharma PLC has appointed Crowe LLP as its new auditor, replacing CLA Evelyn Partners Limited. Crowe will handle the audit for the 2024 financial year, with shareholder approval for their reappointment to be sought at the 2025 Annual General Meeting. This change in auditors could impact ImmuPharma’s financial operations and transparency, potentially affecting stakeholders’ confidence and the company’s market positioning.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Their portfolio includes novel treatments for autoimmune diseases and anti-infectives, with a lead program targeting Systemic Lupus Erythematosus and Chronic Idiopathic Demyelinating Polyneuropathy.
YTD Price Performance: -28.31%
Average Trading Volume: 1,423,547
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £4.98M
See more data about IMM stock on TipRanks’ Stock Analysis page.
